Barasertib

Cat. No.: HY-10127

CAS No.: 722543-31-9

Molecular Formula: $C_{26}H_{31}FN_7O_6P$

Molecular Weight: 587.54

Target: Aurora Kinase; Apoptosis

Pathway: Cell Cycle/DNA Damage; Epigenetics; Apoptosis

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 33 mg/mL (56.17 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.7020 mL	8.5101 mL	17.0201 mL
	5 mM	0.3404 mL	1.7020 mL	3.4040 mL
	10 mM	0.1702 mL	0.8510 mL	1.7020 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline
   Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution
2. Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.17 mg/mL (3.69 mM); Clear solution
4. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.17 mg/mL (3.69 mM); Clear solution
5. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.17 mg/mL (3.69 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC_{50} of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells[1].

IC_{50} & Target	Aurora B 0.37 nM (IC_{50})
In Vitro	Barasertib-HQPA (3 μM, 3 hours) significantly decreases expression of the phosphorylated forms of histone H3 in freshly isolated leukemia cells[1]. Barasertib-hydroxyquinazoline pyrazol anilide (HQPA)] is converted rapidly to the active Barasertib-HQPA in plasma[2]. Barasertib-HQPA is used for the in vitro experiments[3]. Barasertib-HQPA induces a marked anti-proliferative effect accompanied by the appearance of a polyploid population, which in most cases led to apoptosis[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Barasertib (AZD1152, 25 mg/kg) markedly suppresses the growth and weights of AZD1152-treated tumors[1]. Barasertib (AZD1152, 5 mg/kg) enhances the ability of vincristine or daunorubicin to inhibit the proliferation of human MOLM13 leukemic xenografts[1]. Barasertib (AZD1152, (10-150 mg/kg/d) potently inhibited the growth of human colon, lung, and hematologic tumor xenografts (mean tumor growth inhibition range, 55% to z100%; $P < 0.05$) in immunodeficient mice[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female immune-deficient BALB/c nude mice (MOLM13 cells injected)[1].
Dosage:	5 or 25 mg/kg.
Administration:	Intraperitoneal injection 4 times a week or every another day.
Result:	Inhibited the growth of human MOLM13 cells growing as xenografts using an immunodeficient murine model.

CUSTOMER VALIDATION

- Science. 2017 Dec 1;358(6367):eaan4368.
- Nat Commun. 2023 Oct 10;14(1):6332.
- Nat Commun. 2019 Apr 18;10(1):1812
- Clin Cancer Res. 2019 Jul 15;25(14):4552-4566.
- Biomed Pharmacother. 2023 Aug 25;166:115343.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Yang J, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007 Sep

[2]. Wilkinson RW, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007 Jun 15;13(12):3682-8.

[3]. Evans RP, et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol. 2008 Feb;140(3):295-302.

[4]. Oke A, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009 May 15;69(10):4150-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA